These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38482234)

  • 1. Disulfidptosis-related genes of prognostic signature and immune infiltration features in hepatocellular carcinoma supported by bulk and single-cell RNA sequencing data.
    Wang Y; Yuan Z; Zhu Q; Ma J; Lu Q; Xiao Z
    J Gastrointest Oncol; 2024 Feb; 15(1):377-396. PubMed ID: 38482234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disulfidptosis-related signature predicts prognosis and characterizes the immune microenvironment in hepatocellular carcinoma.
    Tang J; Peng X; Xiao D; Liu S; Tao Y; Shu L
    Cancer Cell Int; 2024 Jan; 24(1):19. PubMed ID: 38195525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
    Xiong Y; Kong X; Mei H; Wang J; Zhou S
    Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
    Chen X; Liang Q; Zhou Y
    Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel disulfidptosis-associated expression pattern in breast cancer based on machine learning.
    Wang Z; Du X; Lian W; Chen J; Hong C; Li L; Chen D
    Front Genet; 2023; 14():1193944. PubMed ID: 37456667
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
    Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
    Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
    Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
    Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
    Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel prognostic signature and immune microenvironment characteristics associated with disulfidptosis in papillary thyroid carcinoma based on single-cell RNA sequencing.
    Liao Z; Cheng Y; Zhang H; Jin X; Sun H; Wang Y; Yan J
    Front Cell Dev Biol; 2023; 11():1308352. PubMed ID: 38033866
    [No Abstract]   [Full Text] [Related]  

  • 10. Disulfidptosis and ferroptosis related genes predict prognosis and personalize treatment for hepatocellular carcinoma.
    Liu JF; Huang L; Zhou XP; Li CR; Liu MF; Liang YH; Yu QH; Wu JR
    Transl Cancer Res; 2024 Feb; 13(2):496-514. PubMed ID: 38482398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
    Wei J; Wang J; Chen X; Zhang L; Peng M
    PeerJ; 2024; 12():e16819. PubMed ID: 38317842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
    Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
    Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated analysis of disulfidptosis-related immune genes signature to boost the efficacy of prognostic prediction in gastric cancer.
    Li J; Yu T; Sun J; Ma M; Zheng Z; He Y; Kang W; Ye X
    Cancer Cell Int; 2024 Mar; 24(1):112. PubMed ID: 38528532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of disulfidptosis-related genes with immune infiltration in hepatocellular carcinoma.
    Li XM; Liu SP; Li Y; Cai XM; Zhang SB; Xie ZF
    Heliyon; 2023 Aug; 9(8):e18436. PubMed ID: 37520990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer.
    Xu L; Wang S; Zhang D; Wu Y; Shan J; Zhu H; Wang C; Wang Q
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16511-16523. PubMed ID: 37712959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constructing a disulfidptosis-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing and weighted co-expression network analysis.
    Tian Z; Song J; She J; He W; Guo S; Dong B
    Apoptosis; 2024 Oct; 29(9-10):1632-1647. PubMed ID: 38760515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
    Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
    Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.
    Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X
    Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.